MX340436B - Formulacion farmaceutica estable con descoloramiento limitado. - Google Patents

Formulacion farmaceutica estable con descoloramiento limitado.

Info

Publication number
MX340436B
MX340436B MX2011002364A MX2011002364A MX340436B MX 340436 B MX340436 B MX 340436B MX 2011002364 A MX2011002364 A MX 2011002364A MX 2011002364 A MX2011002364 A MX 2011002364A MX 340436 B MX340436 B MX 340436B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
formulation
stable pharmaceutical
discoloration
limited
Prior art date
Application number
MX2011002364A
Other languages
English (en)
Other versions
MX2011002364A (es
Inventor
Matsushita Takeshi
Mochizuki Yusuke
Original Assignee
Daiichi Sankyo Healthcare Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42005183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340436(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Healthcare Co Ltd filed Critical Daiichi Sankyo Healthcare Co Ltd
Publication of MX2011002364A publication Critical patent/MX2011002364A/es
Publication of MX340436B publication Critical patent/MX340436B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Se proporciona una preparación farmacéutica oral para administración oral que contiene ácido tranexámico y ácido ascórbico, que es excelente en estabilidad sin que se descolore. La preparación farmacéutica sólida para administración oral que contiene ácido tranexámico y ácido ascórbico, en donde la preparación farmacéutica sólida contiene además un copolímero de alcohol polivinílico y/o un alcohol polivinílico parcialmente saponificado.
MX2011002364A 2008-09-12 2009-09-09 Formulacion farmaceutica estable con descoloramiento limitado. MX340436B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008235354 2008-09-12
PCT/JP2009/065700 WO2010029930A1 (ja) 2008-09-12 2009-09-09 変色が抑制された安定な医薬製剤

Publications (2)

Publication Number Publication Date
MX2011002364A MX2011002364A (es) 2011-04-04
MX340436B true MX340436B (es) 2016-07-08

Family

ID=42005183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011002364A MX340436B (es) 2008-09-12 2009-09-09 Formulacion farmaceutica estable con descoloramiento limitado.

Country Status (9)

Country Link
EP (1) EP2335697B1 (es)
JP (1) JP5498387B2 (es)
KR (1) KR101623608B1 (es)
CN (1) CN102137663B (es)
BR (1) BRPI0918539A2 (es)
HK (1) HK1152651A1 (es)
MX (1) MX340436B (es)
TW (1) TWI445527B (es)
WO (1) WO2010029930A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670693B1 (ko) * 2009-10-20 2016-10-31 다이이찌 산쿄 헬스케어 가부시키가이샤 변색 및 냄새가 억제된 필름 코팅정
JP2013049671A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤
JP6245786B2 (ja) * 2011-10-17 2017-12-13 大同化成工業株式会社 医薬用結合剤及び該結合剤を用いた製剤
CN103054861A (zh) * 2012-12-29 2013-04-24 北京阜康仁生物制药科技有限公司 一种含氨甲环酸的复方固体制剂
EP3173101B1 (en) * 2014-07-25 2020-10-21 Mitsubishi Chemical Corporation Polyvinyl alcohol particles, pharmaceutical binder using same, pharmaceutical tablet, sustained-release pharmaceutical tablet, and method for producing polyvinyl alcohol particles
WO2018199282A1 (ja) * 2017-04-28 2018-11-01 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
JP2019081757A (ja) * 2017-10-31 2019-05-30 武田コンシューマーヘルスケア株式会社 固形製剤の製造方法
CN112822995B (zh) * 2018-10-09 2023-06-02 帝斯曼知识产权资产管理有限公司 局部组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243825A (ja) * 1991-01-25 1992-08-31 Ss Pharmaceut Co Ltd 色素沈着症治療剤
JPH093348A (ja) * 1995-06-20 1997-01-07 Lion Corp 色素の変色抑制方法及び色素配合組成物
EP1323404B1 (en) 2000-08-29 2013-10-16 Nisshin Kasei Co.,Ltd. Hard capsule
JP2004217655A (ja) 2002-12-27 2004-08-05 Dai Ichi Seiyaku Co Ltd 美白用組成物
JP2004250376A (ja) * 2003-02-20 2004-09-09 Lion Corp 医薬組成物用色素、医薬組成物用色素の製造方法、医薬組成物及び医薬組成物の変色・退色防止方法
US8277844B2 (en) * 2003-08-20 2012-10-02 Shionogi & Co., Ltd. Coating composition
JP2005068115A (ja) * 2003-08-28 2005-03-17 Pola Chem Ind Inc 安定な皮膚外用剤
JP2005314403A (ja) * 2004-03-31 2005-11-10 Dai Ichi Seiyaku Co Ltd 新規美白用組成物
WO2006003965A1 (ja) * 2004-06-30 2006-01-12 Daiichi Sankyo Healthcare Co., Ltd. 美白組成物
JP5614826B2 (ja) 2005-07-13 2014-10-29 塩野義製薬株式会社 退色を抑制した製剤
JP2007091670A (ja) 2005-09-29 2007-04-12 Shionogi & Co Ltd 退色が抑制された着色カプセル
JP2007197410A (ja) * 2006-01-30 2007-08-09 Lion Corp フィルムコーティング錠
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
KR101602000B1 (ko) * 2008-08-06 2016-03-17 다이이찌 산쿄 헬스케어 가부시키가이샤 안정한 트라넥삼산과 아스코르브산 함유 의약 조성물
KR101640958B1 (ko) * 2008-09-05 2016-07-19 다이이찌 산쿄 헬스케어 가부시키가이샤 유효 성분이 경계를 사이에 두고 존재하여 이루어지는 의약 고형 제제

Also Published As

Publication number Publication date
EP2335697A4 (en) 2011-08-17
MX2011002364A (es) 2011-04-04
JP5498387B2 (ja) 2014-05-21
TWI445527B (zh) 2014-07-21
KR20110057151A (ko) 2011-05-31
CN102137663A (zh) 2011-07-27
TW201016212A (en) 2010-05-01
CN102137663B (zh) 2016-09-28
JPWO2010029930A1 (ja) 2012-02-02
WO2010029930A1 (ja) 2010-03-18
HK1152651A1 (en) 2012-03-09
BRPI0918539A2 (pt) 2015-12-08
KR101623608B1 (ko) 2016-05-23
EP2335697B1 (en) 2014-03-12
EP2335697A1 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
MX340436B (es) Formulacion farmaceutica estable con descoloramiento limitado.
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
DK2007429T3 (da) Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
BR112015025576A2 (pt) formulação para óleo de transmissão para redução do consumo de combustível
WO2009063222A3 (en) Solid compositions
WO2010003133A3 (en) Cdk modulators
TR200806298A2 (tr) Farmasötik formülasyon
PH12015501312A1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
MX2019015396A (es) El uso de amisulpride como un anti-emetico.
WO2015075745A3 (en) Turmeric extract containing soft pastilles
WO2009135593A3 (de) Feste arzneimittelformulierung mit verzögerter freisetzung
EP2762154A3 (en) Vaccine composition for transdermal administration
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
MX2015002966A (es) Composicion aditiva de fluido de transferencia de calor.
AT8372U2 (de) Desmopressin umfassende zusammensetzung
UA100394C2 (en) Lipoic acid pellet composition
UA93466C2 (uk) Сигаретний папір з низькою здатністю до займання
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
WO2011000581A3 (en) Raloxifene composition
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013095319A3 (en) Formulations of flurbiprofen and diacerein
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride

Legal Events

Date Code Title Description
FG Grant or registration